ReviewBiomolecules2026
Lifestyle-Associated Biomarkers of Cellular and Whole-Organism Aging: A Practical Roadmap for Human Geroscience Trials.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Aging is a multidimensional biological process that is not adequately captured by chronological age alone. Geroscience-the study of biological mechanisms that drive age-related functional decline and disease susceptibility-therefore requires biomarker frameworks that can identify biological aging trajectories and assess whether lifestyle-associated interventions meaningfully influence aging-related pathways. In this review, we propose a practical, mechanism-based framework for studying lifestyle-associated effects on cellular and whole-organism aging in humans. We examine major biomarker domains, including DNA-methylation-based epigenetic aging clocks, cellular senescence-associated measures, senescence-associated secretory phenotype factors, inflammaging mediators, oxidative stress indicators, mitochondrial function, metabolic and nutrient-sensing pathways, proteomic and metabolomic signatures, microbiome-associated markers, and functional measures of frailty, mobility, cognition, and resilience. We also discuss criteria for biomarker selection in exploratory and multicenter trials, emphasizing biological relevance, analytical validity, responsiveness to intervention, feasibility, reproducibility, and clinical interpretability. Finally, we outline a practical study-design roadmap integrating biospecimen collection, repeated assessments, core and exploratory biomarker panels, and functional endpoints. A biomarker-guided geroscience strategy may provide a practical route for connecting mechanistic aging biology with clinically relevant human studies designed to preserve healthspan and functional independence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.